Last reviewed · How we verify
bOPV(Candy)
bOPV(Candy) is a vaccine that targets the SARS-CoV-2 virus.
bOPV(Candy) is a vaccine that targets the SARS-CoV-2 virus. Used for COVID-19 prevention.
At a glance
| Generic name | bOPV(Candy) |
|---|---|
| Sponsor | Chinese Academy of Medical Sciences |
| Modality | Biologic |
| Therapeutic area | Infectious Diseases |
| Phase | Phase 3 |
Mechanism of action
bOPV(Candy) is a vaccine that uses a weakened form of the SARS-CoV-2 virus to stimulate an immune response. This immune response helps the body to recognize and fight the virus, providing protection against COVID-19.
Approved indications
- COVID-19 prevention
Common side effects
- Pain, redness, or swelling at the injection site
Key clinical trials
- Study of Concomitant Administration of the sIPV and DTaP or MMR (PHASE4)
- Clinic Trial to Evaluate the Safety and Immunogenicity by Different Sequential Schedules of bOPV and IPV (PHASE3)
- Trail To Evaluate the Immune Effects of Primary and Booster Immunizations With Poliovirus Vaccine (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- bOPV(Candy) CI brief — competitive landscape report
- bOPV(Candy) updates RSS · CI watch RSS
- Chinese Academy of Medical Sciences portfolio CI